Antares Pharma, Inc. (ATRS)

[jab91252]

"Five patients (10.2 percent) had a treatment-emergent adverse event; one patient in the oral MTX group experienced mild and transient nausea. Some patients in the delivery device group had slight to barely perceptible erythema at the injection site after administration."

It is not crystal clear but I'm guessing the break down is as you guess.

Out of the five, one in the oral group reported a TEAE (mild and transient nausea - typical kind of treatment-emergent adverse event for oral delivery) and the rest or "some patients" in the sub Q group reported the slight to barely perceptible erythema at the injection site.

I agree the reported TEAE's are not a real concern and as the report notes: "No patients experienced bleeding, ecchymosis, or hematoma at the injection site or required countermeasures during the study. No patients discontinued the study because of an injection site reaction."